Bermejo-Padilla S, León-Torres K, Prieto-Rivera JC, Espinosa-García E

Language: Spanish
References: 15
Page: 112-116
PDF size: 210.41 Kb.

ABSTRACT

Introduction: we present the case of a patient with hypokalemic periodic paralysis (HPP), which is a type of muscular channelopathy caused by a genetic alteration. Clinical case: a 13-year-old male adolescent with no significant family history. He started with episodes of flaccid paralysis of the four extremities upon awakening, the duration was variable, and without compromise of mental functions. In one of the episodes, severe hypokalemia (1.6 mmol/L) was documented, with recovery after electrolyte correction. HPP was suspected, requesting a genetic panel in which a heterozygous pathogenic variant was identified in the CACNA1S gene, classifying it as type 1 HPPH. Conclusions: HPP is a diagnostic and therapeutic challenge; its early identification can help to reduce comorbidities in these patients.

REFERENCES

1. Statland JM, Barohn RJ. Muscle channelopathies: myotonias and periodic paralyses. Contin (Minneap Minn). 2013; 19(6): 1598-1614.

2. Fontaine B. Periodic paralysis. Adv Genet. 2008; 63: 3-23.

3. Weber F, Lehmann-Horn F. Hypokalemic periodic paralysis. 2002. In: Adam MP, Ardinger HH, Pagon RA et al. Seattle (WA): University of Washington, Seattle; 1993-202.

4. Latorre R, Purroy F. Parálisis periódica hipocaliémica: revisión sistemática de casos publicados. Rev Neurol. 2020; 71(9): 317-325.

5. Gutmann L, Conwit R. Hypokalemic periodic paralysis. In: Shefner JM, Wilterdink JL (eds). UpToDate. Waltham MA: UpToDate Inc.; 2020. Available in: https://www.uptodate.com/contents/hypokalemic-periodic-paralysis?search=parálisisperiódicahipopotasémica&source=search_result&selectedTitle=1~18&usage_type=default&display_rank=1#H1

6. CACNA1A calcium voltage-gated channel subunit alpha1 A [Homo sapiens (human)] -Gene- NCBI [Internet]. Available in: https://www.ncbi.nlm.nih.gov/gene/773

7. Fialho D, Griggs RC, Matthews E. Periodic paralysis. Handbook of Clinical Neurology. 2018; 148: 505-520. Available in: http://dx.doi.org/10.1016/B978-0-444-64076-5.00032-6

8. Sangkuhl K, Dirksen RT, Alvarellos ML, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for CACNA1S. Pharmacogenet Genomics. 2020; 30(2): 34-43.

9. Elbaz A, Vale-Santos J, Jurkat-Rott K, Lapie P, Ophoff RA, Bady B et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNLIA3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Am J Hum Genet. 1995; 56(2): 374-380.

10. Kim SH, Kim UK, Chae JJ, Kim DJ, Oh HY, Kim BJ et al. Identification of mutations including de novo mutations in Korean patients with hypokalaemic periodic paralysis. Nephrol Dial Transplant. 2001; 16(5): 939-944.

11. Chalissery AJ, Munteanu T, Langan Y, Brett F, Redmond J. Diverse phenotype of hypokalaemic periodic paralysis within a family. Pract Neurol. 2018; 18(1): 60-65.

12. Aquino J, Rocha AP, Reis AL. Parálisis periódica hipocalémica familiar?: una causa poco frecuente de parálisis flácida aguda. Rev Neurol. 2016; 63(10): 478-479.

13. Jitpimolmard N, Matthews E, Fialho D. Treatment updates for neuromuscular channelopathies. Curr Treat Options Neurol. 2020; 22(34): 1-20.

14. Gonsalves SG, Dirksen RT, Sangkuhl K, Pulk R, Alvarellos M, Vo T et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes Stephen. Clin Pharmacol Ther. 2019; 105(6): 1338-1344.

15. Matthews E, Portaro S, Ke Q, Sud R, Haworth A, Davis MB et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology. 2011; 77(22): 1960-1964.